Annovis Bio Q4 2022 Earnings Report $4.84 -0.05 (-1.00%) As of 01/31/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Annovis Bio EPS ResultsActual EPS-$0.38Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAnnovis Bio Revenue ResultsActual Revenue$0.06 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnnovis Bio Announcement DetailsQuarterQ4 2022Date4/3/2023TimeN/AConference Call ResourcesANVS Earnings History Annovis Bio Earnings HeadlinesAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31 at 8:37 PM | financialpost.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31 at 8:37 PM | financialpost.comUnveiling 7 High-Potential Stocks for 2025Welcome to 2025—a year brimming with exceptional investment possibilities! Our comprehensive guide, "7 Stocks Set to Soar," has been carefully curated to help you enhance your portfolio this year. Stay Ahead with Cutting-Edge Trends This year, advancements in artificial intelligence are driving transformative changes across various sectors. From AI-powered healthcare innovations to intelligent automation in manufacturing, these technological breakthroughs are creating fertile ground for select companies to thrive. Our guide delves into how these trends are shaping the future and spotlighting the stocks positioned to capitalize on them.February 1, 2025 | Darwin (Ad)Annovis Bio, Inc. Announces Proposed Public OfferingJanuary 31 at 8:14 PM | globenewswire.comAnnovis Bio Secures U.S. Patent for Neuroprotective Drug BuntanetapJanuary 17, 2025 | msn.comAnnovis Bio granted U.S. patent covering buntanetapJanuary 14, 2025 | markets.businessinsider.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS), a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
